.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 6,894,051

« Back to Dashboard

Claims for Patent: 6,894,051

Title: Crystal modification of a N-phenyl-2-pyrimidineamine derivative, processes for its manufacture and its use
Abstract:The invention relates to a new crystalline form of the methanesulfonic acid addition salt of 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2 -ylamino)phenyl]benzamide of formula 1, which may be used for example for tumor therapy.
Inventor(s): Zimmermann; Jurg (Basel, CH), Sutter; Bertrand (Hesingue, FR), Burger; Hans Michael (Allschwil, CH)
Assignee: Novartis AG (Basel, CH)
Application Number:09/463,097
Patent Claims: 1. A crystalline form of the monomethanesulfonic acid addition salt of a compound of formula I, ##STR3##

which is non-hygroscopic in a glass climatic chamber at 25.degree. C. and relative humidities up to and including 93%.

2. A crystalline form according to claim 1 of the methanesulfonic acid addition salt of a compound of formula I, which comprises at least 95% by weight crystals of the .beta.-modification and remains dry at 93% relative humidity and 25.degree. C.

3. A crystalline form according to claim 1 of the methanesulfonic acid addition salt of a compound of formula I, which comprises at least 99% by weight crystals of the .beta.-modification and remains dry at 93% relative humidity and 25.degree. C.

4. A crystalline form according to claim 1 of the methanesulfonic acid addition salt of a compound of formula I, which comprises at least 99% by weight crystals of the .beta.-modification and has a melting point below 225.degree. C.

5. A crystalline form according to claim 1 of the methanesulfonic acid addition salt of a compound of formula I, which comprises at least 99% by weight crystals of the .beta.-modification and has a melting point of less than 217.degree. C., defined as the start of melting in the differential scanning calorimetry thermogram.

6. A crystalline form according to claim 1 of the methanesulfonic acid addition salt of a compound of formula I, which shows on X-ray diffraction a peak at an angle of refraction 2theta of 20.degree., said peak having a relative line intensity of about 65% as compared to the most intense line in the diagram.

7. A crystalline form according to claim 3 of the methanesulfonic acid addition salt of a compound of formula I, which shows in an X-ray diffraction diagram lines having a relative line intensity, as compared to the most intense line in the diagram, of about 20% or more at the following angles of refraction 2theta: 9.7.degree., 13.9.degree., 14.7.degree., 17.5.degree., 18.2.degree., 20.0.degree., 20.6.degree., 21.1.degree., 22.1.degree., 22.7.degree., 23.8.degree., 29.8.degree. and 30.8.degree..

8. A crystalline form according to claim 5 of the methanesulfonic acid addition salt of a compound of formula I, which has a melting point of about 217.degree. C., defined as the start of melting in the differential scanning calorimetry diagram, and which shows essentially the X-ray diffraction diagram as illustrated in FIG. 2/3,

wherein the angle of refraction, 2 theta, is plotted on the horizontal axis and the relative line intensity on the vertical axis.

9. A pharmaceutical composition, comprising the .beta.-crystal form according to claim 1 of the methanesulfonic acid addition salt of a compound of formula I and a pharmaceutically acceptable carrier.

10. A process for the preparation of the .beta.-crystal form of the methanesulfonic acid addition salt of a compound of formula I ##STR4##

which comprises a) digesting another crystal form or an amorphous starting material of the methanesulfonic acid addition salt of a compound of formula I with a suitable polar solvent in suspension at a temperature between 20 and 50.degree. C., or b) dissolving another crystal form or an amorphous starting material of the methanesulfonic acid addition salt of a compound of formula I, in a polar solvent at a suitable temperature of 25.degree. C. up to the reflux temperature of the reaction mixture, and then initiating crystallisation by adding a small amount of the .delta.-crystal form as seed crystal at a temperature between 20 and 70.degree. C.

11. A crystalline form according to claim 1 of the methanesulfonic acid addition salt of a compound of formula I, which comprises at least 90% by weight crystals of the .beta.-modification and remains dry at 93% relative humidity and 25.degree. C.

12. A method for treating a tumor disease in a patient, which comprises administering to the patient an effective amount of the methanesulfonic acid addition salt of a compound of the formula ##STR5##

in its .beta.-crystal modification.

13. A crystalline form of the methanesulfonic acid addition salt of a compound of formula ##STR6##

which displays x-ray diffraction peaks at 9.7.degree. and 20.0.degree. 2 theta.

14. A crystalline form of claim 13 which displays x-ray diffraction peaks having a relative line intensity, as compared to the most intense line in the diagram, of about 20% or more at the following angles of refraction 2 theta: 9.7.degree., 13.9.degree., 14.7.degree., 17.5.degree., 18.2.degree., 20.0.degree., 20.6.degree., 21.1.degree., 22.1.degree., 22.7.degree., 23.8.degree., 29.8.degree. and 30.8.degree..

15. A crystalline form of the monomethanesulfonic acid addition salt of a compound of formula I, ##STR7##

characterized by the presence of the peak marked (1) in the x-ray diffraction pattern depicted in FIG. 1/3.

16. A crystalline form according to claim 15 which essentially shows the x-ray diffraction pattern depicted in FIG. 1/3.

17. A crystalline form according to claim 15 having needle-shaped crystals.

18. A crystalline form according to claim 15 which has a melting point of about 226.degree. C. defined as the start of melting in the differential scanning calorimetry diagram.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc